Morningstar brands and products Company Portfolio ...

Utilizing its proprietary rabbit B Cell Select platform, the company aims to capitalize on the lucrative $81 billion anti-aging market by enhancing diagnostic and therapeutic approaches.

CAR T-cell therapy may offer better outcomes when diffuse large B-cell lymphoma (DLBCL) doesn’t respond to treatment or relapses.

Did non-relapse mortality rates vary by CAR T cell therapy product and how may this inform treatment choice? Yes. Among patients with large B cell lymphoma, we found a higher NRM rate of 7.4% in ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.